Search
Aficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigationalAficamten is a cardiac myosin inhibitor. … [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesSynonyms: (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamideOseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalThe authors concluded that oseltamivir use in healthy adults had small, non-specific effects on symptoms (where the time to first alleviation of symptoms was only reduced from 7 to 6.3 days), it had no … They recommend the use of oseltamivir in people with a higher risk of developing complications including children younger than 2 years, people over 65 years, people with some chronic conditions or immunosuppression
Synonyms: Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-Products: FLUHALT FOR ORAL SUSPENSION 60 mg/ 5 ml, OSEFLU 45 MG KAPSÜL, 10 ADETCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamideKojic acid
go.drugbank.com/drugs/DB01759ApprovedMixtures: Ultra-Potent 2% Kojic Acid GlowingCategories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingSulfameter
go.drugbank.com/drugs/DB06821ApprovedLong acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Synonyms: Sulfa-5-methoxypyrimidineAlosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnAlosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. … Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes.
Categories: Heterocyclic Compounds, 1-Ring, Serotonin 5-HT3 Receptor AntagonistsSynonyms: 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-oneCamsirubicin
go.drugbank.com/drugs/DB13103InvestigationalGPX-150 has been used in trials studying the treatment of Soft Tissue Sarcoma and Advanced Solid Tumors - Phase 1 Population.
Synonyms: 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-, 5-imino-13-deoxydoxorubicinMebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Mixtures: L-OMBRIX-DUET, L-OMBRIX-DUETCategories: Heterocyclic Compounds, 2-RingL-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalA non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Synonyms: L-Glutaminsäure-5-amid, Glutamic acid 5-amideInternational brands: L-Glutamine PowerVadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP2B6 InducersSynonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-